Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2006-05-09
2011-11-08
Leavitt, Maria (Department: 1633)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S018000
Reexamination Certificate
active
08053627
ABSTRACT:
This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and/or treatment of demyelination disorders.
REFERENCES:
patent: 5175384 (1992-12-01), Krimpenfort et al.
patent: 5175385 (1992-12-01), Wagner et al.
patent: 5210015 (1993-05-01), Gelfand et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 7306905 (2007-12-01), Ron et al.
patent: 2002/0116730 (2002-08-01), Allen et al.
patent: 2006/0068496 (2006-03-01), Kelly
patent: 2006/0280685 (2006-12-01), Popko et al.
patent: 2006/0282905 (2006-12-01), Popko et al.
patent: 2010/0281548 (2010-11-01), Popko et al.
Scientific Considerations Related to Developing Follow-On Protein Products. Division of Dockets Management U.S. Food and Drug Administration Nov. 12, 2004, pp. 1-12.
Tassabehji et al., Human Molecular Genetics, 2003, vol. 12, Review Issue 2 R229-R237.
Lees et al., A little stress is good: IFN-gamma, demyelination, and multiple sclerosisJ Clin Invest. Feb. 2007;117(2):297-299.
Gao et al., Interferon-γ Protects against Cuprizone-Induced DemyelinationMolecular and Cellular Neuroscience vol. 16, Issue 4, Oct. 2000, pp. 338-349.
Lucchinetti et al., Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment Curr. Opin. Neurol. vol. 14(3), Jun. 2001, pp. 259-269.
Brown MD, Schatzlein AG, Uchegbu IF.Gene delivery with synthetic (non viral) carriers. Int J Pharm. Oct. 23, 2001;229(1-2):1-21.
Zabner et al., Cellular and molecular barriers to gene transfer by a cationic lipid.J Biol Chem. Aug. 11, 1995;270(32):18997-9007.
Lawrence Steinmana, and Scott S. Zamvilb, Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis doi:10.1016/j.it.2005.08.014 Trends in Immunology vol. 26, Issue 11, Nov. 2005, pp. 565-571.
Compston FRCP et al., Multiple sclerosis The Lancet vol. 372, Issue 9648, Oct. 25, 2008-Oct. 31, 2008, pp. 1502-1517.
Srivastava SP,et al., Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase J Biol Chem. Jan. 23, 1998;273(4):2416-23.
Agresti, et al. Reversible inhibitory effects of interferon-gamma and tumour necrosis factor-alpha on oligodendroglial lineage cell proliferation and differentiation in vitro. Eur J Neurosci. 1996; 8(6): 1106-16.
Agresti, et al. Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes. Eur J Neurosci. 1998; 10(9): 2975-83.
Alexander, et al. Socs1 is a critical inhibitor of interferon-gamma signaling and prevents the potentially fatal action of the cytokine. Cell. 1999; 98: 597-608.
Andrews, et al. TNFalpha potentiates IFNgamma-induced cell death in oligodendrocyte progenitors. J Neurosci Res. 1998; 54(5): 574-83.
Baerwald, et al. Developing and mature oligodendrocytes respond differently to the immune cytokine interferon-gamma. J Neurosci Res. 1998; 52(2): 230-9.
Baerwald, et al. Major histocompatibility complex heavy chain accumulation in the endoplasmic reticulum of oligodendrocytes results in myelin abnormalities. J Neurosci Res. 2000; 59(2): 160-9.
Becher, et al. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol. 1999; 45(2): 247-50.
Billiau, A. Interferon-γ. biology and role in pathogenesis. Adv Immunol. 1996; 62: 61-130.
Bordignon, et al. Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hemtopoietic long-term cultures of ADA-deficient marrow cells. Proc Natl Acad Sci USA. 1989; 86(17): 6748-52.
Boyce, et al. A selective inhibitor of elF2alpha dephosphorylation protects cells from ER stress. Science. 2005; 307(5711): 935-9.
Brenner, et al. GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci. 1994; 14(3 Pt 1): 1030-7.
Brück, et al. Remyelination in multiple sclerosis. J Neurol Sci. 2003; 206(2): 181-5.
Brummelkamp, et al. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002; 296(5567): 550-3.
Brummelkamp, et al. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002; 2(3): 243-7.
Bullen, et al. Neutralization of interferon-gamma in neonatal SOCS1-/- mice prevents fatty degeneration of the liver but not subsequent inflammatory disease. Immunol. 2001; 104: 92-8.
Calabresi, et al. Cytokine gene expression in cells derived from CSF of multiple sclerosis patients. J Neuroimmunol. 1998; 89(1-2): 198-205.
Caplen, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 2001; 98(17): 9742-7.
Chan-Hui, et al. Applications of eTag assay platform to systems biology approaches in molecular oncology and toxicology studies. Clinical Immunology. 2003; 111(2): 162-74.
Chernajovsky, et al. Gene therapy for autoimmune diseases: quo vadis? Nat Rev Immunol. 2004; 4(10): 800-11.
Chew, et al. Interferon-gamma inhibits cell cycle exit in differentiating oligodendrocyte progenitor cells. Glia. 2005; 52(2): 127-43.
Chong, et al. gamma-Interferon signaling in pancreatic beta-cells is persistent but can be terminated by overexpression of suppressor of cytokine signaling-1. Diabetes. 2001; 50: 2744-51.
Coetzee, et al. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell. 1996; 86(2): 209-19.
Connor, et al. Growth arrest and DNA damage-inducible protein GADD34 assembles a novel signaling complex containing protein phosphatase 1 and inhibtor 1. Mol Cell Biol. 2001; 21(20): 6841-50.
Correll, et al. Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells. Proc Natl Acad Sci USA. 1989; 86(22): 8912-6.
Culver, et al. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci USA. 1991; 88(8): 3155-9.
Dell'Albani, et al. Oligodendroglial survival factors, PDGF-AA and CNTF, activate similar JAK/STAT signaling pathways. J Neurosci Res. 1998; 54(2): 191-205.
Dighe, et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994; 1(6): 447-56.
Doerflinger, et al. Inducible site-specific recombination in myelinating cells. Genesis. 2003; 35(1): 63-72.
Economides, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003; 9(1): 47-52.
Einhauer, A. et al. The Flag™ peptide, a versatile fusion tag for the purification of recombinant proteins. J Biochem Biophys Methods. 2001; 49(1-3): 455-65.
Federici, et al. Impaired IFN-gamma-dependent inflammatory response in human keratinocytes overexpressing the suppressor of cytokine signaling 1. J Immunol. 2002; 169(1): 434-43.
Flodström, et al. Target cell defense prevents development of diabetes after viral infection. Nature Immunol. 2001; 3: 373-82.
Fuss, B. et al. Purification and analysis of in vivo-differentiated oligodendrocytes expressing the green fluorescent protein. Dev Biol. 2000; 218(2): 259-74.
Gao, X. et al. Advanced transgenic and gene-targeting approaches. Neurochem Res. 1999; 24(9): 1181-1188.
Gao, X. et al. Interferon-γ protects against cuprizone-induced demyelination. Mol Cell Neurosci. 2000; 16(4): 338-49.
Glabinski, et al. Chemokine expression in GRO mice (lacking interferon-gamma) with experimental autoimmune encephalomyelitis. J Neurovirol. 1999; 5(1): 95-101.
Gonzales, J.M. et al. Expression of dominant negative IFN-γ receptor on mouse oligodendrocytes. GLIA. 2005; 51(1): 22-34.
Hammond, et al. Argonaute2, a link b
Lin Wensheng
Popko Brian
Leavitt Maria
University of Chicago
Wilson Sonsini Goodrich & Rosati
LandOfFree
Methods for treating demyelination disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating demyelination disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating demyelination disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265476